Description
Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages.In VitroLigstroside increases mRNA expression of SIRT1, CREB1, complex I, and GPx1 in SH-SY5Y-APP 695 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoLigstroside (50 mg/kg; a supplemented diet for 6 months) protects against mitochondrial dysfunction in models of early Alzheimer's disease and brain ageing. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NMRI mice, aged 12 months Dosage: 50 mg/kg Administration: Received a supplemented diet for 6 months (equivalent to 6.25 mg/kg b.w.) Result: Showed improved spatial working memory; Restored brain ATP levels in aged mice and led to a significant life extension compared to aged control animals.Form:Solid